Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate b cell growth

Journal of Virology

Volumn 88, Issue 10, 2014, Pages 5706-5717

  Caccuri, Francesca ^a,b   Giagulli, Cinzia ^a   Reichelt, Joachim ^c   Martorelli, Debora ^d   Marsico, Stefania ^e   Bugatti, Antonella ^a   Barone, Ines ^e   Rusnati, Marco ^a   Guzman, Carlos A ^c   Dolcetti, Riccardo ^d   Caruso, Arnaldo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; MATRIX PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P17; SIV MATRIX PROTEIN; UNCLASSIFIED DRUG;

ADAPTATION; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL ACTIVITY; CELL GROWTH; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERNALIZATION; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAJI CELL; SIGNAL TRANSDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS;

B-LYMPHOCYTES; CELL PROLIFERATION; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE PRODUCTS, GAG; HIV ANTIGENS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL MATRIX PROTEINS;

EID: 84899069315     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03142-13     Document Type: Article

References (65)

1. Fiorentini S, Giagulli C, Caccuri F, Magiera A, Caruso A. 2010. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS. Pharmacol. Ther. 128:433-444. http://dx.doi.org/10.1016/j.pharmthera.2010.08.005.
2. Fiorentini S, Riboldi E, Facchetti F, Avolio M, Fabbri M, Tosti G, Becker PD, Guzman CA, Sozzani S, Caruso A. 2008. HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype. Proc. Natl. Acad. Sci. U. S. A. 105:3867-3872. http://dx.doi.org/10.1073/pnas.0800370105.
3. Caccuri F, Giagulli C, Bugatti A, Benetti A, Alessandri G, Ribatti D, Marsico S, Apostoli P, Slevin MA, Rusnati M, Guzman CA, Fiorentini S, Caruso A. 2012. HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc. Natl. Acad. Sci. U. S. A. 109:14580-14585. http://dx.doi.org/10.1073/pnas.1206605109.
4. Popovic M, Tenner-Racz K, Pelser C, Stellbrink HJ, van Lunzen J, Lewis G, Kalyanaraman VS, Gallo RC, Racz P. 2005. Persistence of structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 102:14807-14812. http://dx.doi.org/10.1073/pnas.0506857102.
5. De Francesco MA, Baronio M, Fiorentini S, Signorini C, Bonfanti C, Poiesi C, Popovic M, Grassi M, Garrafa E, Bozzo L, Lewis GK, Licenziati S, Gallo RC, Caruso A. 2002. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc. Natl. Acad. Sci. U. S. A. 99:9972-9977. http://dx.doi.org/10.1073/pnas.142274699.
6. Vitale M, Caruso A, De Francesco MA, Rodella L, Bozzo L, Garrafa E, Grassi M, Gobbi G, Cacchioli A, Fiorentini S. 2003. HIV-1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases their ability to secrete proinflammatory cytokines. Br. J. Haematol. 120:337-343. http://dx.doi.org/10.1046/j.1365-2141.2003.04053.x.
7. Marini E, Tiberio L, Caracciolo S, Tosti G, Guzman CA, Schiaffonati L, Fiorentini S, Caruso A. 2008. HIV-1 matrix protein p17 binds to monocytes and selectively stimulates MCP-1 secretion: role of transcriptional factor AP-1. Cell Microbiol. 10:655-666. http://dx.doi.org/10.1111/j.1462-5822.2007.01073.x.
8. Avolio M, Caracciolo S, Tosti G, Vollero L, Fiorentini S, Caruso A. 2008. HIV-1 matrix protein p17 prevents loss of CD28 expression during IL-2-induced maturation of naive CD8+ T cells. Viral Immunol. 21:189-202. http://dx.doi.org/10.1089/vim.2007.0095.
9. Giagulli C, Magiera AK, Bugatti A, Caccuri F, Marsico S, Rusnati M, Vermi W, Fiorentini S, Caruso A. 2012. HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8-like chemokine activity on monocytes through Rho/ROCK activation. Blood 119:2274-2283. http: //dx.doi.org/10.1182/blood-2011-06-364083.
10. Giagulli C, Marsico S, Magiera AK, Bruno R, Caccuri F, Barone I, Fiorentini S, Andò S, Caruso A. 2011. Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One 6:e17831. http://dx.doi.org/10.1371/journal.pone.0017831.
11. Sharp PM, Bailes E, Chaudhuri RR, Rodenburg CM, Santiago MO, Hahn BH. 2001. The origins of acquired immune deficiency syndrome viruses: where and when? Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:867-876. http://dx.doi.org/10.1098/rstb.2001.0863.
12. Kirchhoff F. 2010. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 8:55-67. http://dx.doi.org/10.1016/j.chom.2010.06.004.
13. Bushman FD, Malani N, Fernandes J, D'Orso I, Cagney G, Diamond TL, Zhou H, Hazuda DJ, Espeseth AS, König R, Bandyopadhyay S, Ideker T, Goff SP, Krogan NJ, Frankel AD, Young JA, Chanda SK. 2009. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog. 5:e1000437. http://dx.doi.org/10.1371/journal.ppat .1000437.
14. Ortiz M, Bleiber G, Martinez R, Kaessmann H, Telenti A. 2006. Patterns of evolution of host proteins involved in retroviral pathogenesis. Retrovirology 3:11-18. http://dx.doi.org/10.1186/1742-4690-3-11.
15. Longdon B, Hadfield JD, Webster CL, Obbard DJ, Jiggins FM. 2011. Host phylogeny determines viral persistence and replication in novel hosts. PLoS Pathog. 7:e1002260. http://dx.doi.org/10.1371/journal.ppat .1002260.
16. Streicker DG, Turmelle AS, Vonhof MJ, Kuzmin IV, McCracken GF, Rupprecht CE. 2010. Host phylogeny constrains cross-species emergence and establishment of rabies virus in bats. Science 329:676-679. http://dx .doi.org/10.1126/science.1188836.
17. The Chimpanzee Sequencing and Analysis Consortium. 2005. Initial sequence of the chimpanzee genome and comparison with the human genome. Nature 437:69-87. http://dx.doi.org/10.1038/nature04072.
18. McLean CY, Reno PL, Pollen AA, Bassan AI, Capellini TD, Guenther C, Indjeian VB, Lim X, Menke DB. 2011. Human-specific loss of regulatory DNA and the evolution of human-specific traits. Nature 471:216-219. http://dx.doi.org/10.1038/nature09774.
19. Wain LV, Bailes E, Bibollet-Ruche F, Decker JM, Keele BF, Van Heuverswyn F, Li Y, Takehisa J, Ngole EM, Shaw GM, Peeters M, Hahn BH, Sharp PM. 2007. Adaptation of HIV-1 to its human host. Mol. Biol. Evol. 24:1853-1860. http://dx.doi.org/10.1093/molbev/msm110.
20. Mwaengo DM, Novembre FJ. 1998. Molecular cloning and characterization of viruses isolated from chimpanzees with pathogenic human immunodeficiency virus type 1 infections. J. Virol. 72:8976-8987.
21. Bibollet-Ruche F, Heigele A, Keele BF, Easlick JL, Decker JM, Takehisa J, Learn G, Sharp PM, Hahn BH, Kirchhoff F. 2012. Efficient SIVcpz replication in human lymphoid tissue requires viral matrix protein adaptation. J. Clin. Invest. 122:1644-1652. http://dx .doi.org/10.1172/JCI61429.
22. Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q, Irvine DJ, Burton DR, Alter G. 2011. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366:8-19. http://dx.doi.org/10.1016/j.jim.2010.12.016.
23. Hill CP, Worthylake D, Bancroft DP, Christensen AM, Sundquist WI. 1996. Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc. Natl. Acad. Sci. U. S. A. 93:3099-3104. http://dx.doi.org/10 .1073/pnas.93.7.3099.
24. Rao Z, Belyaev AS, Fry E, Roy P, Jones IM, Stuart DI. 1995. Crystal structure of SIV matrix antigen and implications for virus assembly. Nature 378:743-747. http://dx.doi.org/10.1038/378743a0.
25. Fiorentini S, Marsico S, Becker PD, Iaria ML, Bruno R, Guzmán CA, Caruso A. 2008. Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17. Vaccine 26:4758-4765. http://dx.doi .org/10.1016/j.vaccine.2008.06.082.
26. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J, Thompson JD, Higgins DG. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7:539.
27. Reichelt J, Dieterich G, Kvesic M, Schomburg D, Heinz DW. 2005. BRAGI: linking and visualization of database information in a 3D viewer and modeling tool. Bioinformatics 21:1291-1293. http://dx.doi.org/10 .1093/bioinformatics/bti138.
28. Bromberg Y, Rost B. 2007. SNAP: predict effect of non-synonymous polymorphisms on function. Nucleic Acids Res. 35:3823-3835. http://dx .doi.org/10.1093/nar/gkm238.
29. Lee J, Horuk R, Rice GC, Bennett GL, Camerato T, Wood WI. 1992. Characterization of two high-affinity human interleukin-8 receptors. J. Biol. Chem. 267:16283-16287.
30. Brat DJ, Bellail AC, Van Meir EG. 2005. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-oncol. 7:122-133. http://dx.doi.org/10.1215/S1152851704001061.
31. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. 1994. Both interleukin-8 receptors independently mediate chemotaxis. Jurkat cells transfected with IL-8R1 or IL-8R2 migrate in response to IL-8, GRO alpha and NAP-2. FEBS Lett. 341:187-192.
32. Hammond ME, Lapointe GR, Feucht PH, Hilt S, Gallegos CA, Gordon CA, Giedlin MA, Mullenbach G, Tekamp-Olson P. 1995. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J. Immunol. 155:1428-1433.
33. Jinquan T, Møller B, Storgaard M, Mukaida N, Bonde J, Grunnet N, Black FT, Larsen CG, Matsushima K, Thestrup-Pedersen K. 1997. Chemotaxis and IL-8 receptor expression in B cells from normal and HIVinfected subjects. J. Immunol. 158:475-484.
34. Fiorentini S, Marini E, Caracciolo S, Caruso A. 2006. Functions of the HIV-1 matrix protein p17. New Microbiol. 29:1-10.
35. Jiang BH, Liu LZ. 2008. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim. Biophys. Acta 1784:150-158. http://dx.doi.org/10 .1016/j.bbapap.2007.09.008.
36. Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC. 2005. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 8:108-118. http://dx.doi.org/10.1038/sj.pcan.4500776.
37. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. 2006. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 46:249-279. http://dx.doi.org/10.1016/j .advenzreg.2006.01.004.
38. Massiah MA, Starich MR, Paschall C, Summers MF, Christensen AM, Sundquist WI. 1994. Three-dimensional structure of the human immunodeficiency virus type 1 matrix protein. J. Mol. Biol. 244:198-223. http: //dx.doi.org/10.1006/jmbi.1994.1719.
39. Verli H, Calazans A, Brindeiro R, Tanuri A, Guimarães JA. 2007. Molecular dynamics analysis of HIV-1 matrix protein: clarifying differences between crystallographic and solution structures. J. Mol. Graph. Model. 26:62-68. http://dx.doi.org/10.1016/j.jmgm.2006.09.009.
40. Feniger-Barish R, Belkin D, Zaslaver A, Gal S, Dori M, Ran M, Ben-Baruch A. 2000. GCP-2-induced internalization of IL-8 receptors: hierarchical relationships between GCP-2 and other ELR(+)-CXC chemokines and mechanisms regulating CXCR2 internalization and recycling. Blood 95:1551-1559.
41. McDonald IK, Thornton JM. 1994. Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 238:777-793. http://dx.doi.org/10.1006/jmbi .1994.1334.
42. Chukkapalli V, Oh SJ, Ono A. 2010. Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain. Proc. Natl. Acad. Sci. U. S. A. 107:1600-1605. http://dx.doi.org/10.1073/pnas.0908661107.
43. Bugatti A, Giagulli C, Urbinati C, Caccuri F, Chiodelli P, Oreste P, Fiorentini S, Orro A, Milanesi L, d'Ursi P, Caruso A, Rusnati M. 2013. Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists. J. Biol. Chem. 288:1150-1161. http: //dx.doi.org/10.1074/jbc.M112.400077.
44. Pinney JW, Dickerson JE, Fu W, Sanders-Beer BE, Ptak RG, Robertson DL. 2009. HIV-host interactions: a map of viral perturbation of the host system. AIDS 23:549-554. http://dx.doi.org/10.1097/QAD.0b013e328325a495.
45. Jäger S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, Shales M, Mercenne G, Pache L, Li K, Hernandez H, Jang GM, Roth SL, Akiva E, Marlett J, Stephens M, D'Orso I, Fernandes J, Fahey M, Mahon C, O'Donoghue AJ, Todorovic A, Morris JH, Maltby DA, Alber T, Cagney G, Bushman FD, Young JA, Chanda SK, Sundquist WI, Kortemme T, Hernandez RD, Craik CS, Burlingame A, Sali A, Frankel AD, Krogan NJ. 2011. Global landscape of HIV-human protein complexes. Nature 481:365-370. http://dx.doi.org/10.1038 /nature10719.
46. Casella CR, Raffini LJ, Panganiban AT. 1997. Pleiotropic mutations in the HIV-1 matrix protein that affect diverse steps in replication. Virology 228:294-306. http://dx.doi.org/10.1006/viro.1996.8355.
47. Bhatia AK, Campbell N, Panganiban A, Ratner L. 2007. Characterization of replication defects induced by mutations in the basic domain andC terminus of HIV-1 matrix. Virology 369:47-54. http://dx.doi.org/10.1016 /j.virol.2007.06.046.
48. Goh GK, Dunker AK, Uversky VN. 2008. A comparative analysis of viral matrix proteins using disorder predictors. Virol. J. 5:126. http://dx.doi.org /10.1186/1743-422X-5-126.
49. Dahiyat BI, Mayo SL. 1997. Probing the role of packing specificity in protein design. Proc. Natl. Acad. Sci. U. S. A. 94:10172-10177. http://dx .doi.org/10.1073/pnas.94.19.10172.
50. Sandberg WS, Terwilliger TC. 1989. Influence of interior packing and hydrophobicity on the stability of a protein. Science 245:54-57. http://dx .doi.org/10.1126/science.2787053.
51. Dunker AK, Brown CJ, Lawson JD, Iakoucheva LM, Obradović Z. 2002. Intrinsic disorder and protein function. Biochemistry 41:6573-6582. http://dx.doi.org/10.1021/bi012159+.
52. Uversky VN, Oldfield CJ, Dunker AK. 2005. Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling. J. Mol. Recognit. 18:343-384. http://dx.doi.org/10.1002/jmr.747.
53. Dyson HJ, Wright PE. 2005. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell. Biol. 6:197-208. http://dx.doi.org/10.1038 /nrm1589.
54. Bannert N, Kurth R, Medstrand P, van de Lagemaat LN, Mager DL. 2002. Retroelement distributions in the human genome: variations associated with age and proximity to genes. Genome Res. 12:1483-1495. http: //dx.doi.org/10.1101/gr.388902.
55. Bannert N, Kurth R. 2004. Retroelements and the human genome: new perspectives on an old relation. Proc. Natl. Acad. Sci. U. S. A. 101:S14572-S14579.
56. Ryan FP. 2004. Human endogenous retroviruses in health and disease: a symbiotic perspective. J. R. Soc. Med. 97:560-565. http://dx.doi.org/10 .1258/jrsm.97.12.560.
57. Rambaut A, Posada D, Crandall KA, Holmes EC. 2004. The causes and consequences of HIV evolution. Nat. Rev. Genet. 5:52-61. http://dx.doi .org/10.1038/nrg1246.
58. Peyerl FW, Bazick HS, Newberg MH, Barouch DH, Sodroski J, Letvin NL. 2004. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J. Virol. 78:13901-13910. http://dx.doi .org/10.1128/JVI.78.24.13901-13910.2004.
59. Kent SJ, Fernandez CS, Dale CJ, Davenport MP. 2005. Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity. Trends Microbiol. 13:243-246. http://dx.doi.org/10.1016 /j.tim.2005.03.011.
60. Crawford H, Prado JG, Leslie A, Hué S, Honeyborne I, Reddy S, van der Stok M, Mncube Z, Brander C, Rousseau C, Mullins JI, Kaslow R, Goepfert P, Allen S, Hunter E, Mulenga J, Kiepiela P, Walker BD, Goulder PJ. 2007. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLAB* 5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. J. Virol. 81:8346-8351. http://dx.doi.org/10.1128/JVI .00465-07.
61. Holmes EC. 2003. Error thresholds and the constraints to RNA virus evolution. Trends Microbiol. 11:543-546. http://dx.doi.org/10.1016/j.tim .2003.10.006.
62. Overington J, Donnelly D, Johnson MS, Sali A, Blundell TL. 1992. Environment-specific amino acid substitution tables: tertiary templates and prediction of protein folds. Protein Sci. 1:216-226.
63. Gong S, Blundell TL. 2008. Discarding functional residues from the substitution table improves predictions of active sites within threedimensional structures. PLoS Comput. Biol. 4:e1000179. http://dx.doi .org/10.1371/journal.pcbi.1000179.
64. Feichtinger H, Putkonen P, Parravicini C, Li SL, Kaaya EE, Böttiger D, Biberfeld G, Biberfeld P. 1990. Malignant lymphomas in cynomolgus monkeys infected with simian immunodeficiency virus. Am. J. Pathol. 137:1311-1315.
65. Gaidano G, Carbone A, Dalla-Favera R. 1998. Pathogenesis of AIDSrelated lymphomas: molecular and histogenetic heterogeneity. Am. J. Pathol. 152:623-630.